Rapid in vivo preclinical screening service for the pharmaceutical development of new drug candidates.
Drug discovery: Amylgen's positioning

One of major Amylgen's achievements:
By using its non transgenic mouse model of Alzheimer's disease, Amylgen has been able to bring to Anavex Life Sciences Corp. the proof of concept in vivo of the efficacy of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. Phase 1 single ascending dose (SAD) clinical trial has successfully been completed and a multiple ascending dose trial is ongoing.
http://anavex.com/press_release_2011_11_14.html
